IRIS
MONDELLO, Patrizia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.784
NA - Nord America 1.770
AS - Asia 316
SA - Sud America 2
OC - Oceania 1
Totale 3.873
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.767
IE - Irlanda 533
SE - Svezia 394
PL - Polonia 298
CN - Cina 229
IT - Italia 209
UA - Ucraina 101
GB - Regno Unito 89
FI - Finlandia 58
DE - Germania 47
SG - Singapore 31
VN - Vietnam 24
BE - Belgio 18
FR - Francia 15
IN - India 15
RU - Federazione Russa 11
IR - Iran 4
JP - Giappone 4
NL - Olanda 4
AT - Austria 3
IL - Israele 3
JO - Giordania 3
BR - Brasile 2
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
CA - Canada 1
CZ - Repubblica Ceca 1
HK - Hong Kong 1
LI - Liechtenstein 1
MX - Messico 1
PA - Panama 1
RO - Romania 1
TH - Thailandia 1
Totale 3.873
Salva come PNG Salva come JPEG
Città #
Dublin 533
Chandler 412
Warsaw 298
Nyköping 241
Jacksonville 161
Messina 114
Ashburn 110
Dearborn 94
Princeton 83
Beijing 73
Medford 73
Des Moines 59
Ann Arbor 58
Cambridge 51
Lancaster 49
Houston 35
Wilmington 34
Boardman 33
Woodbridge 28
Dong Ket 24
Jinan 23
San Mateo 23
Seattle 22
Shenyang 22
New York 19
Falls Church 18
Brussels 16
Singapore 16
Ningbo 12
Nanchang 11
Nanjing 11
Los Angeles 9
Haikou 8
Helsinki 8
Zhengzhou 7
Auburn Hills 6
Fairfield 6
Hangzhou 6
Pune 6
Redwood City 6
Taizhou 6
Tianjin 6
Guangzhou 5
Hyderabad 5
Jiaxing 5
Kunming 5
Norwalk 5
Piazza Armerina 5
Washington 5
Cagliari 4
Changsha 4
Edinburgh 4
Hebei 4
Kyoto 4
Amman 3
Chengdu 3
Gaithersburg 3
Lappeenranta 3
Milan 3
Nuremberg 3
Recanati 3
Rome 3
Scarsdale 3
Vienna 3
Ardabil 2
Bologna 2
Castrolibero 2
Charlottesville 2
Chicago 2
Clearwater 2
Florence 2
Foggia 2
Gela 2
Genoa 2
Hefei 2
Joinville 2
Monmouth Junction 2
Mountain View 2
Saint Petersburg 2
San Giovanni La Punta 2
San Pietro Clarenza 2
Strasbourg 2
Taiyuan 2
Tappahannock 2
Waanrode 2
Amsterdam 1
Andover 1
Atlanta 1
Augusta 1
Bangkok 1
Baotou 1
Bremen 1
Brno 1
Brooklyn 1
Catania 1
Dallas 1
Eden Prairie 1
Fuzhou 1
Gallatin 1
Gostar 1
Totale 2.972
Salva come PNG Salva come JPEG
Nome #
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. 225
Kinase regulation of human MHC class i molecule expression on cancer cells 109
Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma? 102
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 95
Emerging markers of cachexia predict survival in cancer patients. 88
Bendamustine with Rituximab Is Safe and Effective As FRONT LINE Therapy in Elderly B-CLL Patients. an ITALIAN RETROSPECTIVE MULTICENTER Experience 86
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 78
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations 76
90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment. 73
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. 71
Originator Erythropoietin Alpha Vs Biosimilar Erythropoietin Alpha vs Erythropoietin Zed Plus Liposomial Iron and b12 and Folates in Patients with Refractory Anemia. Five Center Retrospective Study 67
90 Y-ibritumomab tiuxetan: A nearly forgotten opportunity 67
Biosimilar Erythropoietin Alpha Is Effective As Originator Erythropoietin Alpha Plus Liposomial Iron and B12 and Folates in Patients with Refractory Anemia: A Retrospective Real-Life Approach 66
Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression. 66
Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial. 64
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma. 63
Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach 63
Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients 61
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 61
Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut. 60
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 60
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 59
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 59
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 58
Thyroid function, autoimmunity and nodules in hematological malignancies 58
Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy? 57
Complications of trauma patients admitted to the ICU in level i academic trauma centers in the United States 57
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 57
Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma 56
Efficacy and Safety Of Bendamustine In Combination With Rituximab For Elderly Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia. A Retrospective Multicenter Study 55
Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease. 55
Glutamine treatment attenuates the development of organ injury induced by zymosan administration in mice 55
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 55
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model 54
Efficacy of Intravenous Hydrocortisone Treatment in Refractory Neonatal Seizures: A Report on Three Cases 54
Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? 53
Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options 53
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 53
90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward? 51
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 51
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 50
ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study 50
De novo mutation in SLC25A22 gene: expansion of the clinical and electroencephalographic phenotype 50
Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent 47
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma 47
Congenital heart disease in down syndrome 47
Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats 46
Palmitoylethanolamide Reduces Early Renal Dysfunction and Injury Caused by Experimental Ischemia and Reperfusion in Mice. 46
R-CHOP versus R-COMP: are they really equally effective? 46
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 46
null 46
Circulating Mitotic Figures In A Patient With Dual Infection By Epstein-Barr Virus And Cytomegalovirus. 45
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 45
Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms 45
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP 44
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma 44
The heart in Anderson-Fabry disease 44
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death 40
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine. 39
An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. 38
A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies 37
Emerging drugs for diffuse large B-cell lymphoma. 36
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib 36
Primary central nervous system lymphoma: Novel precision therapies 35
PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB 34
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors 31
Effects of Apocynin, A Nadph-oxidase Inhibitor, In Contrast-induced Nephropathy 30
Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study 27
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma 26
Questionable Validity of Cardiac Risk Score on the Basis of the NSABP B-31 Model 25
Fatal Hepatocellular Carcinoma in a Patient with Occult Hepatitis B Virus Infection following the Administration of R-CHOP for Diffuse Large B-Cell Lymphoma. 24
Treatment of Aggressive B Cell Lymphomas: Updates in 2019 24
Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy 23
Pim kinases in hematological malignancies: where are we now and where are we going? 22
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse 21
PHOENIX rises: Genomic-based therapies for diffuse large B cell lymphoma 19
Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma 15
Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma 3
Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies 2
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma 2
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma 2
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma 2
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma 1
Insights into the tumor microenvironment of B cell lymphoma 1
Insights into the tumor microenvironment of B cell lymphoma 1
Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy 1
Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments 1
Inhibition of NF-κB DNA Binding Suppresses Myeloma Growth via Intracellular Redox and Tumor Microenvironment Modulation 1
null 1
Totale 4.139
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.035
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.035
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020467 41 24 7 19 17 82 89 50 21 44 60 13
2020/2021651 66 22 118 29 80 40 40 80 54 70 20 32
2021/2022557 3 44 19 19 30 19 20 19 8 101 65 210
2022/20231.507 139 130 86 120 92 143 14 80 635 18 37 13
2023/2024333 23 53 24 26 20 57 18 33 5 23 20 31
2024/20258 8 0 0 0 0 0 0 0 0 0 0 0
Totale 4.139